JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 12 May 2006. doi:10.1136/jcp.2005.035758
Journal of Clinical Pathology 2007;60:57-61
Copyright © 2007 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jcp.2005.035758v1
60/1/57    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zimpfer, A.
Right arrow Articles by Dirnhofer, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zimpfer, A.
Right arrow Articles by Dirnhofer, S.

ORIGINAL ARTICLE

Construction and validation of a bone marrow tissue microarray

Annette Zimpfer1, Sharon Schönberg1, Alessandro Lugli1, Claudio Agostinelli2, Stefano A Pileri2, Philip Went1, Stephan Dirnhofer1

1 Institute of Pathology, University Hospital of Basel, Basel, Switzerland
2 Pathologic Anatomy & Haematopathology Unit, Institute of Haematology and Clinical Oncology "L. & A. Seràgnoli", University of Bologna, Bologna, Italy

Correspondence to:
Dr Stephan Dirnhofer
Institute of Pathology, University Hospital of Basel, Schönbeinstrasse 40, Basel CH-4031, Switzerland; sdirnhofer{at}uhbs.ch Background: The use of tissue microarrays (TMAs) is now a generally accepted method for the investigation of solid tumours. However, little is known about the applicability of the TMA technique for analysis of patients with acute leukaemia. A bone marrow (BM)-TMA analysis with 15 different immunohistochemical markers was performed. The TMA was validated by comparison with the corresponding full tissue sections.

Materials and methods: A BM-TMA comprising 148 cases of acute leukaemia, including 115 acute myeloid leukaemia (AML) and 33 acute lymphoblastic leukaemia (ALL) cases, was constructed. Expression of CD3, CD10, CD15, CD20, CD34, CD61, CD68, CD79a, CD99, CD117, CD138, myeloperoxidase, haemoglobin A1, glycophorin and terminal deoxynucleotidyl transferase was immunohistochemically analysed. 50 cases of the TMA were directly compared with the corresponding full tissue section to validate the results.

Results: Morphologically and immunohistochemically, 6 (4%) of 148 cases and 765 (11%) cores of 6912 individual analyses were not evaluable. A direct comparison of TMA cases with conventional full sections showed a concordance of the results of 100%.

Conclusions: The small size of bone-marrow biopsies and the presence of bony trabeculae do not preclude construction and analysis of acute leukaemia TMAs. Acute leukaemia cases on TMA displayed the characteristic phenotypic profiles expected in different AML and ALL subtypes. Therefore, the TMA technique is also a promising method for high-throughput analysis of combined marker expression and clinicopathological correlations in patients with leukaemia.


Abbreviations: ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; BM-TMA, bone marrow tissue microarray; cHL, classical Hodgkin’s lymphoma; FAB, French–American–British; GEP, gene expression profiling; H&E, haematoxylin and eosin; MPO, myeloperoxidase; TdT, terminal deoxynucleotidyl transferase; TMA, tissue microarray







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.